Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158981 | 1.00 | CA12 (0.43) | CA12CA1CA7CA14CYP2C19 | |
| SCHEMBL6569877 | 0.88 | CA12 (0.41) | CA12CA1CA7CA14CYP2C19 | |
| SCHEMBL27159095 | 0.88 | CTSK (0.41) | CA12CA1CA7CA14CYP2C19 | |
| SCHEMBL27204213 | 0.88 | CTSK (0.41) | CA12CA1CA7CA14CYP2C19 | |
| SCHEMBL2525924 | 0.88 | CTSS (0.43) | CA12CA1CA7CA14CXCR2 | |
| SCHEMBL16245145 | 0.88 | CTSS (0.43) | CA12CA1CA7CA14CXCR2 | |
| SCHEMBL193093 | 0.86 | KCNN4 (0.44) | CYP2C19HIF1ACXCR2KMT2AMEN1 | |
| SCHEMBL24096094 | 0.84 | CYP2C19 (0.41) | CA12CA1CA7CA14CYP2C19 | |
| SCHEMBL9828908 | 0.83 | KDM4E (0.51) | CXCR2KMT2AMEN1NPC1GAA | |
| SCHEMBL9828915 | 0.83 | KDM4E (0.51) | CXCR2KMT2AMEN1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4332089-A1 | METHOD FOR PREPARING AMINO ACIDS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| EP-3423454-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-09 | — | — | EP | disclosed |
| CN-108602823-A | As deubiquitinating enzymes（DUB）The spiral shell of inhibitor-condensation pyrrolidin derivatives | 特殊治疗有限公司 | 2018-09-28 | — | — | CN | disclosed |
| EP-0119705-B1 | OCTAPEPTIDE VASOPRESSIN ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4684622-A | CYCLIC OLIGOPEPTIDES, DISULFIDE LINKAGE | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-04 | — | — | US | disclosed |
| US-4599324-A | VASODILATORS | SMITHKLINE BECKMAN CORPORATION (US) | 1986-07-08 | — | — | US | disclosed |
| EP-0182626-A2 | V1-vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4587045-A | Intermediates for preparing octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-06 | — | — | US | disclosed |
| US-4542124-A | Octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1985-09-17 | — | — | US | disclosed |
| EP-0119705-A2 | Octapeptide vasopressin antagonists | SMITHKLINE BECKMAN CORPORATION (US) | 1984-09-26 | — | — | EP | disclosed |
| US-4469679-A | DIURETICS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | CA12 1728/4885CA1 1427/4885CA7 1327/4885 |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | CA12 1728/4885CA1 1427/4885CA7 1327/4885 |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | CA12 1728/4885CA1 1427/4885CA7 1327/4885 |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | CA12 1728/4885CA1 1427/4885CA7 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.